for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Swedish Orphan Biovitrum AB (publ)

SOBIV.ST

Latest Trade

153.95SEK

Change

-1.35(-0.87%)

Volume

434,831

Today's Range

153.25

 - 

155.75

52 Week Range

144.70

 - 

234.30

As of on the Stockholm Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
155.30
Open
154.95
Volume
434,831
3M AVG Volume
17.66
Today's High
155.75
Today's Low
153.25
52 Week High
234.30
52 Week Low
144.70
Shares Out (MIL)
294.09
Market Cap (MIL)
46,181.59
Forward P/E
14.77
Dividend (Yield %)
--

Next Event

Q4 2019 Swedish Orphan Biovitrum AB (publ) Earnings Release

Latest Developments

More

Sobi Says Completed Tender Offer For All Outstanding Shares Of Dova Pharmaceuticals

Swedish Orphan Biovitrum Q3 EBITA Up At SEK 1.01 Bln

Sobi To Acquire Dova Pharmaceuticals

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Swedish Orphan Biovitrum AB (publ)

Swedish Orphan Biovitrum publ AB is a Sweden-based pharmaceutical company. The Company develops, manufactures and sells medications within hemophilia, autoimmune diseases, metabolic diseases and cancer supportive care. The Company’s product portfolio is divided into three business segments: the Core Products segment offers pharmaceuticals within Inflammation area, and Genetics and metabolic therapeutic area; the Partner Products segment offers about 40 pharmaceuticals within hematology, oncology and emergency medicines, and the ReFacto Manufacturing segment. The Company has subsidiaries in Sweden, Denmark, Finland, Norway, United Kingdom and France, among others. On September 9, 2013, the Company acquired the full rights to develop and commercialize Kineret (anakinra) from Amgen, the biotechnology company based in the United States.

Industry

Biotechnology & Drugs

Contact Info

Tomtebodavagen 23A

+46.8.6972000

https://www.sobi.com/

Executive Leadership

Hakan Bjorklund

Independent Chairman of the Board

Guido Oelkers

President, Chief Executive Officer

Henrik Stenqvist

Chief Financial Officer

Anne Marie De Jonge Schuermans

Head of Technical Operations

Armin Reininger

Head of Medical and Scientific Affairs

Key Stats

2.43 mean rating - 7 analysts
Sell
Hold
Buy
Revenue (MM, SEK)

2016

5.2K

2017

6.5K

2018

9.1K

2019(E)

13.6K
EPS (SEK)

2016

3.010

2017

4.250

2018

8.930

2019(E)

10.451
Price To Earnings (TTM)
17.41
Price To Sales (TTM)
3.87
Price To Book (MRQ)
2.89
Price To Cash Flow (TTM)
12.22
Total Debt To Equity (MRQ)
57.82
LT Debt To Equity (MRQ)
57.24
Return on Investment (TTM)
13.24
Return on Equity (TTM)
10.35

Latest News

Latest News

CORRECTED-BRIEF-Swedish Orphan Biovitrum Q3 EBITA Up At SEK 1.10 Bln

* Q3 SALES FOR ELOCTA WERE SEK 1,156 M (873) AND SALES FOR ALPROLIX WERE SEK 341 M (255)

CORRECTED-Sweden's Sobi buys rights for emapalumab drug, strengthening inflammation business

Drugmaker Swedish Orphan Biovitrum (Sobi) said on Friday it had reached an exclusive licensing deal with Swiss firm Novimmune SA for the perpetual global rights to emapalumab, a late-stage orphan drug candidate for the treatment of primary Haemophagocytic lymphohistiocytosis...

BRIEF-Sobi appoints Henrik Stenqvist as new CFO

* HENRIK STENQVIST IS JOINING SOBI AS NEW CHIEF FINANCIAL OFFICER

BRIEF-Swedish Orphan Biovitrum says receives positive opinion from CHMP on Anakira

* The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for Anakinra for the treatment of Still’s disease.

UPDATE 1-‍Sobi Q4 tops forecast but 2018 outlook below market expectations​

Rare-disease drug maker Swedish Orphan Biovitrum (Sobi) reported on Thursday a bigger fourth-quarter profit jump than expected but guided for slightly slower profit growth in 2018 than estimated by analysts.

BRIEF-‍Sobi Q4 core profit beats expectations ​

* SAYS SOBI EXPECTS TOTAL REVENUES FOR FULL-YEAR TO BE IN RANGE OF SEK 7,500 - 7,700 M.

UPDATE 1-Sobi to scale up in North America as Q3 beats expectations

Rare-disease drug maker Swedish Orphan Biovitrum (Sobi) reported on Wednesday a bigger jump than expected in quarterly core profit, raised its profit and sales guidance, and said it planned to boost operations in North America.

BRIEF-Swedish Orphan Biovitrum says Alprolix approved for use in Saudi Arabia

* Alprolix approved for treatment of Hemofili B in Saudi Arabia. Source text for Eikon: Further company coverage: (Reporting By Johan Sennero)

BRIEF-Sobi raises outlook as Q3 core profit beats expectations

* Swedish orphan biovitrum says sobi now expects total revenues for full year to be in range of sek 6,300 to 6,400 m (6,100-6,200)

BRIEF-Sobi Q2 EBITA falls, raises 2017 guidance

* Swedish orphan biovitrum Q2 total revenue was SEK 1,639 mln (1,469)

BRIEF-Sobi says COO Raffensperger to leave the company

* Says company and Raffensperger, have come to the agreement that Raffensperger will leave the company to pursue other opportunities. Source text for Eikon: Further company coverage: (Stockholm Newsroom)

BRIEF-Sobi ends discussions to sell Partner Products business area

* Sobi keeps the Partner Products business area as an integral part of the company

BRIEF-Sobi appoints Guido Oelkers as new CEO

* Oelkers joins Sobi from his previous role as CEO at BSN Medical GmbH

BRIEF-Sobi Q1 EBITA SEK 406 mln, repeats outlook

* Says Q1 revenues grew 10 per cent overall, and by 47 percent adjusted for the one-time credit of SEK 322 million received in Q1 2016.

BRIEF-Sobi CEO sees broad interest in Partner Products platform

Swedish Orphan Biovitrum AB CEO Geoffrey McDonough to reporters:

BRIEF-Sobi says expands haemophilia B development portfolio

* Sobi expands haemophilia B development portfolio by adding rFIXFc-XTEN to its collaboration agreement with Bioverativ Source text for Eikon: Further company coverage: (Reporting by Stockholm Newsroom)

BRIEF-Sobi Q4 EBITA lags expectations

* Q4 total revenue of sek 1,292 m (814), an increase of 59 per cent (54 per cent at cer)

Drug maker Sobi eyes sale of Partner Products unit

Swedish drug maker Swedish Orphan Biovitrum (Sobi) <SOBIV.ST> said on Friday it was in talks with a private equity firm regarding a possible sale of its Partner Products business area.

BRIEF-Sobi confirms divestment discussions, shares halted

* Says confirms that company is in discussions with a private equity firm regarding a possible sale of its partner products business area excluding Kineret and Orfadin.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up